QAX 028

Drug Profile

QAX 028

Alternative Names: QAX028

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antiasthmatics; Bronchodilators
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 31 Aug 2010 Discontinued - Phase-II for Chronic obstructive pulmonary disease in European Union (Inhalation)
  • 31 Aug 2010 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA (Inhalation)
  • 25 Aug 2010 Novartis completes a phase II trial (NCT01068613) in Chronic obstructive pulmonary disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top